Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482014 | 1.00 | MAPK1 (0.43) | MAPK1MAP3K12MAP4K4MAPKAPK2PARP1 | |
| SCHEMBL16680537 | 0.86 | MAPK1 (0.41) | MAPK1MAP3K12MAP4K4MAPKAPK2PARP1 | |
| SCHEMBL16680538 | 0.86 | MAPK1 (0.41) | MAPK1MAP3K12MAP4K4MAPKAPK2PARP1 | |
| SCHEMBL15205265 | 0.86 | MAPKAPK2 (0.41) | MAPK1MAPKAPK2ATRKDM4EALDH1A1 | |
| SCHEMBL481969 | 0.80 | CNR2 (0.36) | MAPK1MAP3K12MAP4K4MAPKAPK2ATR | |
| SCHEMBL481968 | 0.80 | CNR2 (0.36) | MAPK1MAP3K12MAP4K4MAPKAPK2ATR | |
| SCHEMBL16678940 | 0.78 | ALOX5AP (0.38) | MAPK1MAP3K12PIK3CA | |
| SCHEMBL16678939 | 0.78 | ALOX5AP (0.38) | MAPK1MAP3K12PIK3CA | |
| SCHEMBL16684552 | 0.77 | MAPK1 (0.43) | MAPK1MAP3K12MAPKAPK2PIK3CA | |
| SCHEMBL16690721 | 0.77 | MAPK1 (0.43) | MAPK1MAP3K12MAPKAPK2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | MAPK1 455/4885MAP3K12 69/4885MAP4K4 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.